Ideas & Insights

After 17 months of internal discussions, the German administration approved a draft bill to implement the EU Anti-Tax Avoidance Directives.

Life sciences companies are on a healthy fundraising pace. What’s predicted for investments and exits for the remainder of 2021?

Join our webcast to learn how cloud ERPs, like Oracle NetSuite, can support organizations navigating clinical and commercial contracts.

Register now to hear insights on the current trends impacting the life sciences industry during this March 11 webcast.

Here are some areas in which CMOs, CROs and life sciences companies with established product pipelines might consider investing right now.

Three veterans of the life sciences private equity and M&A market share intel about dramatic changes in the industry.

The German Ministry of Finance has released new guidance clarifying withholding treatment of IP registered in Germany.

LB&I’s compliance campaign focuses on taxpayer reporting of purchase price allocations in taxable asset acquisitions.

This year, the health care sector could not even wait until the second full week of January to kick off an acquisition announcement spree.

The DoD has updated its DFARS rules from the existing clause to three new clauses to allow enforcement of CMMC for DoD contracts.

UK government provides relief from DAC6, reducing the scope of reporting for UK intermediaries with cross-border transactions.

SPACs have grown in popularity recently as a means of going public. Learn why high-growth companies are using this method.

RSM helped Tanner Pharma overcome challenges with its NetSuite implementation provider, setting a foundation for growth and ongoing support.

What CFOs learned by going through a virtual IPO: hiring, roadshow planning and the process of getting vetted by an outside accounting firm.

After the US presidential election and looking ahead to a new year, most companies are still wondering when the world will return to normal.

Biden plans to expand Medicare, a move that the Congressional Budget Office estimates would cut drug spending by $450 billion over 10 years.

This recorded webcast gives an overview of how, when and why biopharma companies should invest in enterprise resource planning systems.

This webcast gives an overview of the top considerations for life sciences companies looking to repatriate or nearshore supply chains.

With the election approaching, RSM is looking at the economic stakes and the key issues for the life sciences industry.

We suggest stress-testing your supply chain to determine what the actual or opportunity costs of disruption might be.